gileads sovaldi from sa, page-3

and you guys call me crazy for saying $100 SP by 2017.

This article clearly shows we will be worth more than that AND thats only for Hep C!!!!

$100 seems low now.

patient compliance? We would be the number 1 for that. We would cost less. Gilead will throw billions at us and beg us not to compete.

Wondering when these companies will seriously start to worry about our one shot tech. At safety results this year? Or only in 2016 when we are in P2b?

interesting. Great thing is not upto them or anyone else whether we make billions purely upto OUR tech working.

The SP is under $2. Bargain of the century or what?